To include your compound in the COVID-19 Resource Center, submit it here.

ALN-CC5: Phase I/II ongoing

Alnylam said it will narrow its development program for ALN-CC5 to target poor responders to Soliris eculizumab and PNH patients who require Soliris

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE